Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$8.77 -1.6%	$6.81	$4.02 ▼ $13.28	$467.88M	1.97	1.26 million shs	1.46 million shs
MYGN Myriad Genetics	$5.87 -2.7%	$5.05	$3.76 ▼ $29.30	$546.15M	1.89	1.76 million shs	1.95 million shs
SGMO Sangamo Therapeutics	$0.54 +4.3%	$0.52	$0.41 ▼ $3.18	$125.82M	1.18	6.11 million shs	6.10 million shs
ZBIO Zenas BioPharma	$16.71 +5.1%	$12.34	$5.83 ▼ $26.25	$699.05M	N/A	180,579 shs	77,950 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	+9.11%	+46.23%	+21.53%	+56.49%	+33.73%
MYGN Myriad Genetics	-2.58%	+55.81%	+12.92%	+57.03%	-78.43%
SGMO Sangamo Therapeutics	+17.51%	-2.36%	+5.18%	+18.15%	-52.95%
ZBIO Zenas BioPharma	+6.71%	-1.18%	+42.22%	+83.18%	+1,589,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.8661 of 5 stars	3.5	3.0	4.6	3.8	2.5	2.5
MYGN Myriad Genetics	3.7037 of 5 stars	3.1	2.0	4.1	3.0	1.7	0.0
SGMO Sangamo Therapeutics	2.1225 of 5 stars	3.3	2.0	0.0	2.8	0.8	0.6
ZBIO Zenas BioPharma	1.5025 of 5 stars	3.5	0.0	0.0	1.8	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	63.44% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	112.17% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	733.95% Upside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	119.43% Upside

Current Analyst Ratings Breakdown

Latest SGMO, MYGN, ZBIO, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/16/2025	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/15/2025	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00
5/14/2025	SGMO Sangamo Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $5.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.45	$2.06 per share	4.25	$10.05 per share	0.87
MYGN Myriad Genetics	$837.60M	0.65	$0.95 per share	6.20	$4.17 per share	1.41
SGMO Sangamo Therapeutics	$81.71M	1.54	N/A	N/A	$0.08 per share	6.75
ZBIO Zenas BioPharma	$15M	46.60	N/A	N/A	$7.48 per share	2.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	$2.45	3.58	4.24	N/A	16.38%	24.63%	8.97%	N/A
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	N/A
SGMO Sangamo Therapeutics	-$97.94M	-$0.29	N/A	N/A	N/A	-77.48%	-293.05%	-63.85%	N/A
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest SGMO, MYGN, ZBIO, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	N/A	N/A	N/A	$1.25 million	N/A
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	$5.00 million	N/A
8/7/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	-$0.08	-$0.01	-$0.08	$31.68 million	$18.31 million
8/6/2025	Q2 2025	EBS Emergent Biosolutions	-$0.26	$0.16	+$0.42	-$0.22	$148.55 million	$140.90 million
5/15/2025	Q1 2025	ZBIO Zenas BioPharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	$0.05	0.29%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.25	5.66	3.00
MYGN Myriad Genetics	N/A	1.42	1.28
SGMO Sangamo Therapeutics	N/A	1.05	1.05
ZBIO Zenas BioPharma	N/A	6.47	6.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
MYGN Myriad Genetics	99.02%
SGMO Sangamo Therapeutics	56.93%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	3.20%
MYGN Myriad Genetics	2.10%
SGMO Sangamo Therapeutics	4.10%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	53.35 million	51.64 million	Optionable
MYGN Myriad Genetics	2,700	93.04 million	91.09 million	Optionable
SGMO Sangamo Therapeutics	480	233.17 million	223.61 million	Optionable
ZBIO Zenas BioPharma	N/A	41.83 million	34.93 million	N/A

SGMO, MYGN, ZBIO, and EBS Headlines

Recent News About These Companies

Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit

August 13 at 8:43 AM | msn.com

Zenas BioPharma Reports Q2 2025 Financial Results

August 13 at 2:14 AM | tipranks.com

Zenas BioPharma expects cash to fund operations into Q4 of 2026

August 12 at 10:42 PM | msn.com

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12 at 4:31 PM | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12 at 7:05 AM | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?

July 26, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's Why

July 14, 2025 | marketbeat.com

Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma

July 3, 2025 | tipranks.com

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

ZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...

June 17, 2025 | stockhouse.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 17, 2025 | prnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

June 16, 2025 | accessnewswire.comA

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 16, 2025 | globenewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

June 16, 2025 | globenewswire.com

June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, MYGN, ZBIO, and EBS Company Descriptions

Emergent Biosolutions NYSE:EBS

$8.77 -0.14 (-1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$8.72 -0.05 (-0.57%)

As of 06:09 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Myriad Genetics NASDAQ:MYGN

$5.87 -0.16 (-2.65%)

Closing price 04:00 PM Eastern

Extended Trading

$5.88 +0.00 (+0.09%)

As of 06:06 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Sangamo Therapeutics NASDAQ:SGMO

$0.54 +0.02 (+4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$0.53 -0.01 (-1.96%)

As of 06:19 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Zenas BioPharma NASDAQ:ZBIO

$16.71 +0.81 (+5.09%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time